Canbex Therapeutics

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.

Barny Cox Ph.D

Director, Preclinical Operations

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.